Combination chemotherapy regimens using paclitaxel in advanced gastric cancer
| Regimen (reference) | RR | PFS (months) | OS (months) |
| Paclitaxel+platinum21–27 | 22%–46% | 2.9–6 | 7.5–13.8 |
| Paclitaxel+fluoropyrimidine28–32 | 32%–66% | 3–9 | 9.9–14 |
| Paclitaxel+fluoropyrimidine + platinum33–36 | 51%–66% | 4–9 | 6–14 |
OS, median overall survival; PFS, progression-free survival; RR, response rate.